244 related articles for article (PubMed ID: 22799876)
41. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
42. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop.
Guerriero C; Cairns J; Roberts I; Rodgers A; Whittaker R; Free C
Eur J Health Econ; 2013 Oct; 14(5):789-97. PubMed ID: 22961230
[TBL] [Abstract][Full Text] [Related]
43. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Howard P; Knight C; Boler A; Baker C
Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.
Capel M; Mareque M; Álvarez CJ; Lindner L; Oyagüez I
Clin Drug Investig; 2018 Jul; 38(7):611-620. PubMed ID: 29654555
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients.
Christenhusz LC; Prenger R; Pieterse ME; Seydel ER; van der Palen J
Nicotine Tob Res; 2012 Jun; 14(6):657-63. PubMed ID: 22180589
[TBL] [Abstract][Full Text] [Related]
46. Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada.
Mullen KA; Coyle D; Manuel D; Nguyen HV; Pham B; Pipe AL; Reid RD
Tob Control; 2015 Sep; 24(5):489-96. PubMed ID: 24935442
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD.
Huber MB; Präger M; Coyle K; Coyle D; Lester-George A; Trapero-Bertran M; Nemeth B; Cheung KL; Stark R; Vogl M; Pokhrel S; Leidl R
Addiction; 2018 Jun; 113 Suppl 1(Suppl Suppl 1):52-64. PubMed ID: 29243347
[TBL] [Abstract][Full Text] [Related]
48. Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada.
Thanh NX; Jacobs P; Suggett J; McIvor A; Kaplan A
Can Respir J; 2019; 2019():9176504. PubMed ID: 30774739
[TBL] [Abstract][Full Text] [Related]
49. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
Punekar YS; Shukla A; Müllerova H
Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
[TBL] [Abstract][Full Text] [Related]
50. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine.
Hoogendoorn M; Corro Ramos I; Baldwin M; Gonzalez-Rojas Guix N; Rutten-van Mölken MPMH
Value Health; 2019 Mar; 22(3):313-321. PubMed ID: 30832969
[TBL] [Abstract][Full Text] [Related]
51. Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease.
Monninkhof E; van der Valk P; Schermer T; van der Palen J; van Herwaarden C; Zielhuis G
Chron Respir Dis; 2004; 1(1):7-16. PubMed ID: 16281663
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
[TBL] [Abstract][Full Text] [Related]
53. Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis.
Moayeri F; Hsueh YS; Clarke P; Dunt D
Value Health; 2016 Jun; 19(4):363-73. PubMed ID: 27325328
[TBL] [Abstract][Full Text] [Related]
54. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
Trials; 2015 Oct; 16():447. PubMed ID: 26452466
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
56. Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.
Briggs AH; Baker T; Risebrough NA; Chambers M; Gonzalez-McQuire S; Ismaila AS; Exuzides A; Colby C; Tabberer M; Muellerova H; Locantore N; Rutten van Mölken MPMH; Lomas DA
Med Decis Making; 2017 May; 37(4):469-480. PubMed ID: 27317436
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
Chan MC; Tan EC; Yang MC
Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
[TBL] [Abstract][Full Text] [Related]
60. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T
Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
